 As of January 4, 2019 the vaccine has entered phase 2 trials to assess the efficacy of the vaccine in individuals with celiac disease who are given a gluten-challenge test.On June 25, 2019, the phase 2 trial was terminated.The results did not demonstrate protection from gluten exposure when compared to a placebo.